<DOC>
	<DOC>NCT02961556</DOC>
	<brief_summary>This baseline-controlled, open-label, multicenter study evaluates the efficacy and safety of AJG555 orally administered for 2 weeks in pediatric participants with chronic constipation. The safety and efficacy of 12 weeks of administration will also be evaluated.</brief_summary>
	<brief_title>General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Main Participants with chronic constipation Age: 2 years old or older and 14 years old or younger (at the time of the informed consent) Gender: N/A Main Participants with organic constipation or participants suspected of having organic constipation Participants with symptomatic constipation or participants suspected of having symptomatic constipation Participants with druginduced constipation or participants suspected of having druginduced constipation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AJG555</keyword>
	<keyword>Constipation</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Pediatric participants</keyword>
</DOC>